Results for chin-thinner support Phase III plans, Kythera says
This article was originally published in Scrip
Executive Summary
Kythera Biopharmaceuticals will start US Phase III trials this year for its injectable adipolytic agent, ATX-101 (sodium deoxycholate for injection), for reduction of fat under the chin (submental fat), it has confirmed as it detailed promising Phase II results for the first-in-class product.